Objectives: To analyse the market shares of biosimilars in Slovakia and to calculate the potential cost-savings from the use of biosimilars in Slovakia based on two different data sources. Methods: National reimbursement lists from the Czech Republic, Hungary, Poland and Slovakia were used for analyzing the availability of biosimilars with public funding. In addition, the reimbursement dossiers of biosimilars, the justifications of reimbursement decisions by the Slovak Ministry of Health, and final reimbursement decrees, which are published on the webpage of the Slovak Ministry of Health, were utilized for this study. Reimbursement decisions regarding biosimilars by the Slovak Ministry of Health from 2006 to August 2019 were considered and the detailed utilization of biosimilars in 2018 was analyzed based on data from the State Institute for Drug Control. The study was validated based on data from the Slovak National Health Information Center. Results: Fifty four biosimilars were approved by the European Medicines Agency (EMA) in August 2019. Of the total group of licensed biosimilars on the market, 29 biosimilars (54%) were available in the Czech Republic, 28 biosimilars (52%) were available in Poland, and 27 biosimilars (50%) were available in Hungary and 24 biosimilars (44%) were available in Slovakia. Our analysis, based on the data provided by distributors of medicinal products to the State Institute for Drug Control, revealed that the health fund in Slovakia could have saved 35 to 50 million euros per year if biosimilars with marketing authorisations had been available on the Slovak market. The calculations assumed a 25-35% price decrease against the original biological medical products, and that there would be no increase in the utilization of biosimilars in Slovakia. Conclusions: To achieve significant improvement in patient access to biosimilars in Slovakia, a top-down approach establishing targets and quotas for the procurement of biosimilars should be applied.

Center of Health Technology Assessment Semmelweis University Budapest Hungary

Department of Organisation and Management in Pharmacy Faculty of Pharmacy Comenius University in Bratislava Bratislava Slovakia

Faculty of Health Sciences Institute of Public Health Jagiellonian University Medical College Krakow Poland

Faculty of Medicine Institute of Pharmacology and Clinical Pharmacology Comenius University in Bratislava Bratislava Slovakia

Institute for Economic and Social Reforms Bratislava Slovakia

Syreon Research Institute Budapest Hungary

Zobrazit více v PubMed

European Medicines Agency Biosimilars in the EU - Information Guide for Healthcare Professional. (2019). Available online at: https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf (accessed February 18, 2020).

Kawalec P, Stawowczyk E, Tesar T, Skoupa J, Turcu-Stiolica A, Dimitrova M, et al. . Pricing and reimbursement of biosimilars in central and Eastern European Countries. Front Pharmacol. (2017) 8:288. 10.3389/fphar.2017.00288 PubMed DOI PMC

Geynisman DM, De Velasco G, Sewell KL, Jacobs I. Biosimilar biologic drugs: a new frontier in medical care. Postgrad Med. (2017) 129:460–70. 10.1080/00325481.2017.1311196 PubMed DOI

European Medicines Agency Similar Biological Medicinal Products (Overarching Guideline). CHMP/437/04 Rev. 1. (2014). Available online at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf (accessed February 18, 2020).

Kurki P, Van Aerts L, Wolff-Holz E, Giezen T, Skibeli V, Weise M. Interchangeability of biosimilars: a European perspective. BioDrugs. (2017) 31:83–91. 10.1007/s40259-017-0210-0 PubMed DOI

Markus R, Liu J, Ramchandani M, Landa D, Born T, Kaur P. Developing the totality of evidence for biosimilars: regulatory considerations and building confidence for the health- care community. BioDrugs. (2017) 31:175–87. 10.1007/s40259-017-0218-5 PubMed DOI PMC

Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, et al. . Immunogenicity of biologics in chronic in- flammatory diseases: a systematic review. BioDrugs. (2017) 31:299–316. 10.1007/s40259-017-0231-8 PubMed DOI PMC

Annese V, Vecchi M, Bossa F, Bossa F, Calabrese E, Daperno M, et al. Use of biosimilars in inflammatory bowel disease: statements of the Italian group for inflammatory bowel disease. Dig Liver Dis. (2014) 46:963–8. 10.1016/j.dld.2014.07.019 PubMed DOI

Atzeni F, Sebastiani M, Ricci C, Celano A, Gremese E, Iannone F. Position paper of Italian rheumatologists on the use of biosimilar drugs. Clin Exp Rheumatol. (2014) 33:1–4. PubMed

Gomollon F. Biosimilars: are they bioequivalent? Dig Dis. (2014) 32:82–7. 10.1159/000367833 PubMed DOI

Inotai A, Prins CP, Csanadi M, Vitezic D, Codreanu C, Kaló Z. Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars. Expert Opin Biol Ther. (2017) 17:915–26. 10.1080/14712598.2017.1341486 PubMed DOI

Cook JW, McGrath MK, Dixon MD, Switchenko JM, Harvey RD, Pentz RD. Academic oncology clinicians' understanding of biosimilars and information needed before prescribing. Ther Adv Med Oncol. (2019) 11:1758835918818335. 10.1177/1758835918818335 PubMed DOI PMC

Leonard E, Wascovich M, Oskouei S, Gurz P, Carpenter D. Factors affecting health care provider knowledge and acceptance of biosimilar medicines: a systematic review. J Manag Care Spec Pharm. (2019) 25:102–12. 10.18553/jmcp.2019.25.1.102 PubMed DOI PMC

Giuliani R, Tabernero J, Cardoso F, McGregor KH, Vyas M, de Vries EGE. Knowledge and use of biosimilars in oncology: a survey by the European society for medical oncology. ESMO Open. (2019) 4:e000460. 10.1136/esmoopen-2018-000460 PubMed DOI PMC

Danese S, Fiorino G, Raine T, Ferrante M, Kemp K, Kierkus J, et al. . ECCO position statement on the use of biosimilars for inflammatory bowel disease - An update. J Crohn's Colitis. (2017) 11:26–34. 10.1093/ecco-jcc/jjw198 PubMed DOI

Eriksen J, Gustafsson LL, Ateva K, Bastholm-Rahmner P, Ovesjö ML, Jirlow M, et al. . High adherence to the ‘Wise list’ treatment recommendations in Stockholm: a 15-year retrospective review of a multifaceted approach promoting rational use of medicines. BMJ Open. (2017) 7:e014345. 10.1136/bmjopen-2016-014345 PubMed DOI PMC

Jorgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, et al. . Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator in- fliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. (2017) 389:2304–16. 10.1016/S0140-6736(17)30068-5 PubMed DOI

Moorkens E, Simoens S, Troein P, Declerck P, Vulto AG, Huys I. Different policy measures and practices between Swedish counties influence market dynamics: part 1 - Biosimilar and originator infliximab in the hospital setting. BioDrugs. (2019) 33:285–97. 10.1007/s40259-019-00345-6 PubMed DOI PMC

Moorkens E, Jonker-Exler C, Huys I, Declerck P, Simoens S, Vulto AG. Overcoming barriers to the market access of biosimilars in the European Union: the case of biosimilar monoclonal antibodies. Front Pharmacol. (2016) 7:193. 10.3389/fphar.2016.00193 PubMed DOI PMC

Farfan-Portet MI, Gerkens S, Lepage-Nefkens I, Vinck I, Hulstaert F. Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures? Eur J Health Econ. (2014) 15:223–8. 10.1007/s10198-013-0538-4 PubMed DOI PMC

Declerck PJ, Simoens S. A European perspective on the market accessibility of biosimilars. J Biosimilars. (2012) 2:33–40. 10.2147/BS.S33524 DOI

Inotai A, Kaló Z. How to solve financing gap to ensure patient access to patented pharmaceuticals in CEE countries? - the good, the bad, and the ugly ways. Expert Rev Pharmacoecon Outcomes Res. (2019) 19:627–32. 10.1080/14737167.2019.1702524 PubMed DOI

Kaló Z, Annemans L, Garrison LP. Differential pricing of new pharmaceuticals in lower income European countries. Expert Rev Pharmacoecon Outcomes Res. (2013) 13:735–41. 10.1586/14737167.2013.847367 PubMed DOI

Inotai A, Csanádi M, Vitezic D, Francetic I, Tesar T, Bochenek T, et al. Policy practices to maximise social benefit from biosimilars. J Bioequiv Availab. (2017) 9:467–72. 10.4172/jbb.1000346 DOI

Dylst P, Vulto A, Simoens S. Barriers to the uptake of biosimilars and possible solutions: a Belgian case study. Pharmacoeconomics. (2014) 32:681–91. 10.1007/s40273-014-0163-9 PubMed DOI

Tesar T, Hloska A, Wawruch M, Lehocka L, Snopkova M, Masarykova L. Introduction of health technology assessment for medicines in Slovakia. Int J Technol Assess Health Care. (2017) 33:1–5. 10.1017/S026646231700006X PubMed DOI

Slovak Ministry of Health Act No. 363/2011 Coll. on the Scope and Conditions of Payments for Medicines, Medical Devices and Dietetic Foods From Public Health Insurance and Amending Certain Acts. (2011). Available online at: http://www.zakonypreludi.sk/zz/2011-363 (accessed February 18, 2020).

Kuenzel R, Solanic V. Improving the Cost-Effectiveness of Slovakia's Healthcare System. Luxembourg: Publications Office of the European Union. (2018). Available online at: https://ec.europa.eu/info/sites/info/files/economy-finance/eb041_en_0.pdf (accessed February 18, 2020).

European Medicines Agency Medicines. (2019). Available online at: https://www.ema.europa.eu/en/medicines/search_api_aggregation_ema_medicine_types/field_ema_med_biosimilar (accessed August 30, 2019).

Hungarian National Health Insurance Fund Administration The Reimbursement List of Drugs – August 2019. (2019). Available online at: http://www.oep.hu/gyogyszerkereso (accessed August 30, 2019).

State Institute for Drug Control The Reimbursement List of Drugs – 1.8.2019. (2019) Available online at: http://www.sukl.cz/sukl/seznam-cen-a-uhrad-lp-pzlu-k-1-8-2019 (accessed August 30, 2019).

Polish Ministry of Health The Reimbursement List of Drugs - August 2019. (2019). Available online at: https://www.gov.pl/web/zdrowie/obwieszczenie-ministra-zdrowia-z-dnia-27-czerwca-2019-r-w-sprawie-wykazu-refundowanych-lekow-srodkow-spozywczych-specjalnego-przeznaczenia-zywieniowego-oraz-wyrobow-medycznych-na-1-lipca-2019-r (accessed August 30, 2019).

Slovak Ministry of Health The Reimbursement List of Drugs 1.8.2019 – 31.8.2019. (2019). Available online at: https://www.health.gov.sk/Clanok?lieky201908 (accessed August 30, 2019).

Simon-Kucher and Partners Payer's Price & Market Access Policies Supporting a Sustainable Biosimilar Medicines Market. (2016). Available online at: http://www.medicinesforeurope.com/wp-content/uploads/2016/09/Simon-Kucher-2016-Policy-requirements-for-a-sustainable-biosimilar-market-FINAL-report_for-publication.pdf (accessed February 18, 2020).

MCR Consumption of Medicinal Products in Slovakia. (2019). Available online at: https://www.mcr.sk/spotreba-liekov-na-slovensku/ (accessed August 30, 2019).

State Institute for Drug Control About SIDC. (2019). Available online at: https://www.sukl.sk/hlavna-stranka/english-version/about-sidc?page_id=259 (accessed August 30, 2019).

National Health Information Centre About NHIC. (2019). Available online at: http://www.nczisk.sk/en/Pages/default.aspx (accessed August 30, 2019).

Mulcahy AW, Hlavka JP, Case SR. Biosimilar cost savings in the United States: initial experience and future potential. Rand Health Q. (2018) 7:3. PubMed PMC

Kaló Z, Holtorf AP, Alfonso-Cristancho R, Shen J, Ágh T, Inotai A, et al. Need for multicriteria evaluation of generic drug policies. Value Health. (2015) 18:346–51. 10.1016/j.jval.2014.12.012 PubMed DOI

Tesar T, Golias P, Inotai A, Kawalec P, Wawruch M. The impact of implemented regulations on biosimilars in Slovakia. Health Policy Technol. (2019) 8:408–13. 10.1016/j.hlpt.2019.09.004 DOI

Moorkens E, Vulto AG, Huys I, Dylst P, Goldman B, Keuerleber S, et al. . Policies for biosimilar uptake in Europe: an overview. PLoS ONE. (2017) 12:e0190147. 10.1371/journal.pone.0190147 PubMed DOI PMC

Inotai A, Ágh T, Karpenko AW, Zemplényi A, Kaló Z. Behind the subcutaneous trastuzumab hype: evaluation of benefits and their transferability to Central Eastern European Countries. Expert Rev Pharmacoecon Outcomes Res. (2019) 19:105–13. 10.1080/14737167.2019.1554437 PubMed DOI

Brodszky V, Rencz F, Péntek M, Baji P, Lakatos PL, Gulácsi L. A budget impact model for biosimilar infliximab in Crohn's disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia. Expert Rev Pharmacoecon Outcomes Res. (2016) 16:119–25. 10.1586/14737167.2015.1067142 PubMed DOI